Skip to main content
. 2014 Dec;5(6):408–413. doi: 10.3978/j.issn.2078-6891.2014.072

Table 2. Second-line systemic treatment groups.

Group Number of patients (%) Median PFS (months; CI) Median OS (months; CI)
GEM-P 11 (19.6) 3.8 (2.3-8.2) 12.3 (10-40.7)
GEM-FU 16 (28.6) 2.6 (1.8-3.9) 15.1 (8.6-22)
FU-combo 21 (37.5) 2.5 (1.8-4.6) 14.7 (9.6-23.5)
Other* 8 (14.3) 2.8 (2-9) 20.9 (1.8-N/A)

*GEM-P, gemcitabine plus platinum; GEM-FU, gemcitabine plus fluoropyrimidine; FU-combo, fluoropyrimidine combination; CI, confidence interval.